The daily business briefing: November 9, 2020

Published Nov 09 2020 at 12:55 PM GMT

Key
Points

A coronavirus vaccine candidate in development from Pfizer and BioNTech was found to be more than 90 percent effective against COVID-19 in a first interim analysis, the companies announced on Monday.
In an analysis of 94 subjects infected with the coronavirus, the companies said that the early data "indicates a vaccine efficacy rate above 90 percent.
This was a better rate than anticipated.
Pfizer previously said it could seek emergency use authorization from the Food and Drug Administration for its vac.